Frederick M. Hudson - 12 Mar 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 12 Mar 2026
Net transactions value: -$271,725
Form type: 4
Filing time: 16 Mar 2026, 16:07:41 UTC
Previous filing: 25 Feb 2026
SEC: View on sec.gov

Quoteable Key Fact

"Frederick M. Hudson filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 16 Mar 2026."

Quick Takeaways

This page summarizes Frederick M. Hudson's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 16 Mar 2026, 16:07.

What Changed

Previous filing in this sequence was filed on 25 Feb 2026.
Current net transaction value: -$271,725.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hudson Frederick M.	Director	C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE	/s/ Timothy C. Dec, as attorney-in-fact	16 Mar 2026	0001438462

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Sale	$271,725	-5,369	-8.2%	$50.61	60,413	12 Mar 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.